TABLE 2.

Australian pharmaceutical benefits scheme authority criteria for nintedanib in progressive fibrosing interstitial lung disease (PF‐ILD) and ATS/ERS/JRS/ALAT progressive pulmonary fibrosis criteria (PPF) as of May 2023.

	Australian PBS PF‐ILD criteria	ATS/ERS/JRS/ALAT PPF criteria
Diagnosis	Diagnosis other than IPF through a multi‐disciplinary meeting	Any fibrotic ILD other than IPF
	Not due to reversible causes
Physiology	FVC ≥45%
	DLCO ≥30% and ≤ 80%
	FEV1/FVC >0.7
HRCT	HRCT within 12 months of application.
	Affected area of ≥10% on HRCT.
Progression	In the 2 years prior to the application, one of the following: Relative decline of FVC% predicted of ≥10% Relative decline of FVC% predicted of ≥5% and < 10% with either worsening respiratory symptoms or increased fibrosis on HRCT	Two or more of the following within the past 12 months without an alternative explanation: Worsening respiratory symptoms Physiological deterioration: Absolute decline in FVC% predicted ≥5%, or Absolute decline in DLCO %predicted ≥10% Radiological progression: Increased extent or severity of traction bronchiectasis/bronchiolectasis New ground glass opacity with traction bronchiectasis New fine reticulation Increased extent or increased coarseness of reticulation New or increased honeycombing Increased lobar volume loss

Abbreviations: ATS/ERS/JRS/ALAT, American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association; DLCO, diffusing capacity for carbon monoxide; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; HRCT, high‐resolution computed tomography; IPF, idiopathic pulmonary fibrosis; PBS, pharmaceutical benefits scheme; PF‐ILD, progressive fibrosing interstitial lung disease; PPF, progressive pulmonary fibrosis.